Aurobindo Pharma gets US FTC nod for Lannett deal

Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma, has received the necessary approval from the US Federal Trade Commission (FTC) to acquire 100% of the membership interest in Lannett Company LLC. This regulatory clearance marks a critical step towards completing the acquisition, which was initially agreed upon with LANNETT SELLER HOLDCO, INC. The deal is now expected to close before the end of June 2026.

Transaction Details

The acquisition involves Aurobindo Pharma USA Inc purchasing the entire membership interest of Lannett Company LLC. The definitive agreement for this transaction was signed with LANNETT SELLER HOLDCO, INC. The following table outlines the key entities involved in the deal:

Entity	Role
Aurobindo Pharma USA Inc	Acquirer (Wholly Owned Subsidiary)
LANNETT SELLER HOLDCO, INC	Seller
Lannett Company LLC	Target Company

Aurobindo Pharma has committed to informing the stock exchanges of any future developments regarding the deal's completion. The disclosure was made to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.75%	+2.30%	-0.18%	+23.86%	+35.51%	+57.26%

Aurobindo Pharma Limited disclosed that its promoters have not created any new encumbrances on their shareholdings as of March 31, 2026, other than those previously reported to the stock exchanges. The declaration, submitted by K. Nithyananda Reddy on behalf of the promoter group, confirms compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing provides a comprehensive breakdown of the shareholding structure within the promoter group, which collectively holds a majority stake in the pharmaceutical company.

The disclosure states that no fresh encumbrances have been made directly or indirectly on the shares held by the promoters during the financial year ended March 31, 2026. This regulatory filing ensures transparency regarding the pledging or hypothecation of shares by key shareholders. The promoter group's total holding stands at 30,09,48,721 shares, accounting for 51.82% of the total share capital of Aurobindo Pharma.

Shareholding Breakdown

The list of promoters and promoter group entities includes individual shareholders and corporate entities. The largest single holding within the group is attributed to RPR Sons Advisors Private Limited and Mrs. P. Suneela Rani, who jointly hold 19,45,61,357 shares, representing 33.50% of the total share capital. Other significant individual shareholders include Mr. Kambam Nityananda Reddy and Mrs. Kirthi Reddy Kambham.

Promoter and Promoter Group Holdings

Sl. No.	Name	No. of shares held	% of the total share capital
1	Mr. Venkata Ramprasad Reddy Penaka	1,78,33,646	3.07
2	Mr. Kambam Nityananda Reddy	2,53,59,572	4.37
3	Dr. M Sivakumaran	1,43,57,432	2.47
4	Mrs. Rajeswari Kambam	18,08,631	0.31
5	Mrs. Suneela Rani Penaka	1,28,799	0.02
6	Mr. Prasada Reddy Kambham	2,98,373	0.05
7	Mr. K Suryaprakash Reddy	7,380	0.00
8	Mr. M Sumanth Kumar Reddy	15,85,214	0.27
9	Mrs. Kirthi Reddy Kambham	2,00,62,852	3.45
10	Mrs. K Spoorthi	69,39,173	1.19
11	Mrs. Penaka Neha Reddy	-	0.00
12	Trident Chemphar Limited	7,82,241	0.13
13	Axis Clinicals Limited	6,51,920	0.11
14	RPR Sons Advisors Private Limited, Mrs. P. Suneela Rani (Jointly Holding)	19,45,61,357	33.50
15	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Pvt. Ltd. (Jointly Holding)	1,65,72,131	2.85
Total		30,09,48,721	51.82

The document was signed by K. Nithyananda Reddy, an authorised signatory for the promoters and promoter group. The detailed shareholding data was submitted to the National Stock Exchange of India Limited and BSE Limited for their records.